Mostrar el registro sencillo del ítem
Explaining the Variability of Alzheimer Disease Fluid Biomarker Concentrations in Memory Clinic Patients Without Dementia
| dc.rights.license | open | en_US |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | BOUTELOUP, Vincent | |
| hal.structure.identifier | Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept] | |
| dc.contributor.author | PELLEGRIN, Isabelle | |
| dc.contributor.author | DUBOIS, Bruno | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | CHENE, Genevieve | |
| hal.structure.identifier | Institut des Maladies Neurodégénératives [Bordeaux] [IMN] | |
| dc.contributor.author | PLANCHE, Vincent | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | DUFOUIL, Carole | |
| dc.date.accessioned | 2024-10-09T14:31:19Z | |
| dc.date.available | 2024-10-09T14:31:19Z | |
| dc.date.issued | 2024-04-23 | |
| dc.identifier.issn | 1526-632X | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/202352 | |
| dc.description.abstractEn | Background and Objectives: Patients’ comorbidities can affect Alzheimer disease (AD) blood biomarker concentrations. Because a limited number of factors have been explored to date, our aim was to assess the proportion of the variance in fluid biomarker levels explained by the clinical features of AD and by a large number of non–AD-related factors.Methods: MEMENTO enrolled 2,323 individuals with cognitive complaints or mild cognitive impairment in 26 French memory clinics. Baseline evaluation included clinical and neuropsychological assessments, brain MRI, amyloid-PET, CSF (optional), and blood sampling. Blood biomarker levels were determined using the Simoa-HDX analyzer. We performed linear regression analysis of the clinical features of AD (cognition, AD genetic risk score, and brain atrophy) to model biomarker concentrations. Next, we added covariates among routine biological tests, inflammatory markers, demographic and behavioral determinants, treatments, comorbidities, and preanalytical sample handling in final models using both stepwise selection processes and least absolute shrinkage and selection operator (LASSO). Results: In total, 2,257 participants were included in the analysis (median age 71.7, 61.8% women, 55.2% with high educational levels). For blood biomarkers, the proportion of variance explained by clinical features of AD was 13.7% for neurofilaments (NfL), 11.4% for p181-tau, 3.0% for Aβ-42/40, and 1.4% for total-tau. In final models accounting for non–AD-related factors, the variance was mainly explained by age, routine biological tests, inflammatory markers, and preanalytical sample handling. In CSF, the proportion of variance explained by clinical features of AD was 24.8% for NfL, 22.3% for Aβ-42/40, 19.8% for total-tau, and 17.2% for p181-tau. In contrast to blood biomarkers, the largest proportion of variance was explained by cognition after adjustment for covariates. The covariates that explained the largest proportion of variance were also the most frequently selected with LASSO. The performance of blood biomarkers for predicting A+ and T+ status (PET or CSF) remained unchanged after controlling for drivers of variance.Discussion: This comprehensive analysis demonstrated that the variance in AD blood biomarker concentrations was mainly explained by age, with minor contributions from cognition, brain atrophy, and genetics, conversely to CSF measures. These results challenge the use of blood biomarkers as isolated stand-alone biomarkers for AD. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | * |
| dc.title.en | Explaining the Variability of Alzheimer Disease Fluid Biomarker Concentrations in Memory Clinic Patients Without Dementia | |
| dc.title.alternative | Neurology | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1212/wnl.0000000000209219 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 38527237 | en_US |
| bordeaux.journal | Neurology | en_US |
| bordeaux.page | e209219 | en_US |
| bordeaux.volume | 102 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 8 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.institution | CNRS | |
| bordeaux.team | PHARES_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.identifier.funderID | Fondation Plan Alzheimer | en_US |
| bordeaux.identifier.funderID | Avid Radiopharmaceuticals | en_US |
| bordeaux.identifier.funderID | GE Healthcare | en_US |
| bordeaux.identifier.funderID | Fujirebio Europe | en_US |
| hal.identifier | hal-04550079 | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | false | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Neurology&rft.date=2024-04-23&rft.volume=102&rft.issue=8&rft.spage=e209219&rft.epage=e209219&rft.eissn=1526-632X&rft.issn=1526-632X&rft.au=BOUTELOUP,%20Vincent&PELLEGRIN,%20Isabelle&DUBOIS,%20Bruno&CHENE,%20Genevieve&PLANCHE,%20Vincent&rft.genre=article |
